TRVI
MaterialsTrevi Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving TRVI Today?
No stock-specific AI insight has been generated for TRVI yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
TRVI News
20 articles- Trevi Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030Yahoo Finance·May 6, 2026
- Trevi Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 5, 2026
- Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·Apr 30, 2026
- Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026Yahoo Finance·Apr 28, 2026
- Trevi Therapeutics to Participate in Upcoming May EventsYahoo Finance·Apr 23, 2026
- Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?Yahoo Finance·Apr 22, 2026
- Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesYahoo Finance·Apr 20, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate EarningsYahoo Finance·Apr 17, 2026
- Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockBenzinga·Apr 17, 2026
- Trevi Therapeutics Announces Proposed Public Offering of Common StockYahoo Finance·Apr 16, 2026
- A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic CoughYahoo Finance·Apr 5, 2026
- Trevi Therapeutics to Participate in Upcoming EventsYahoo Finance·Apr 1, 2026
- As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?Motley Fool·Mar 23, 2026
- Trevi Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 18, 2026
- Trevi Therapeutics (TRVI) Earnings TranscriptMotley Fool·Mar 18, 2026
- Trevi Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 18, 2026
- Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 18, 2026
- Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 17, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Trevi Therapeutics Inc
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.